Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): a trial of the Eastern Cooperative Oncology Group
The Eastern Cooperative Oncology Group (ECOG) conducted a phase II trial of interleukin-
12 (IL-12) for plateau phase multiple myeloma. Patients were initially treated with IL-12
250ng/kg IV daily for 5 days every 3 weeks. The trial was modified due to toxicity after the
first 16 patients. IL-12 was given 300ng/kg subcutaneously twice weekly for 24 weeks. Of 48
eligible patients, there were 4 objective responses (8.3%), all CR. The median survival and
progression-free survival were 42.8 and 11.4 months. Unacceptable grade 3 or 4 non …
12 (IL-12) for plateau phase multiple myeloma. Patients were initially treated with IL-12
250ng/kg IV daily for 5 days every 3 weeks. The trial was modified due to toxicity after the
first 16 patients. IL-12 was given 300ng/kg subcutaneously twice weekly for 24 weeks. Of 48
eligible patients, there were 4 objective responses (8.3%), all CR. The median survival and
progression-free survival were 42.8 and 11.4 months. Unacceptable grade 3 or 4 non …